Nanomedicines of Hedgehog inhibitor and PPAR-γ agonist for treating liver fibrosis.
about
Design, Synthesis and Biological Evaluation of novel Hedgehog Inhibitors for treating Pancreatic Cancer.Role of glycogen synthase kinase-3β and PPAR-γ on epithelial-to-mesenchymal transition in DSS-induced colorectal fibrosis.Codelivery of small molecule hedgehog inhibitor and miRNA for treating pancreatic cancerDelivery and targeting of miRNAs for treating liver fibrosis.Strategies to prevent and reverse liver fibrosis in humans and laboratory animals.Novel Anti-fibrotic Therapies.Interactions between TGF-β1, canonical WNT/β-catenin pathway and PPAR γ in radiation-induced fibrosis.Hedgehog signalling in liver pathophysiology.Interactions Between the Canonical WNT/Beta-Catenin Pathway and PPAR Gamma on Neuroinflammation, Demyelination, and Remyelination in Multiple Sclerosis.Pharmacokinetics and Biodistribution of GDC-0449 Loaded Micelles in Normal and Liver Fibrotic Mice.Crosstalk Between Peroxisome Proliferator-Activated Receptor Gamma and the Canonical WNT/β-Catenin Pathway in Chronic Inflammation and Oxidative Stress During Carcinogenesis.Demyelination in Multiple Sclerosis: Reprogramming Energy Metabolism and Potential PPARγ Agonist Treatment Approaches.PLA-PEG Nanoparticles Improve the Anti-Inflammatory Effect of Rosiglitazone on Macrophages by Enhancing Drug Uptake Compared to Free Rosiglitazone
P2860
Q33687409-E6DC7E4C-D51D-4134-8173-53821ED1AAC9Q36282521-B0ECBB5B-3F12-4329-9A0A-3CD9C24CF467Q36791689-3EEB71D4-4EEE-4816-9695-846A511F2D9EQ38245905-7E6F888F-E2F1-4E35-918A-6AA3C5571414Q38473640-D9F4F66E-1A5A-4E3C-8A5C-A7ED6CBDECCAQ39377055-A8E8A1CD-512C-48C2-9700-2E6B86C0BA1DQ47109594-B433247A-21D9-4366-BF91-2860E093D306Q47589566-7EEADFDD-D438-43E3-81DE-FDA9E40641ACQ47687993-184A11AB-0C72-4241-ACEF-D5FFE290838BQ51000204-0559086B-64F1-4C9C-AED9-E702585E273CQ52715797-2D0C837F-DDFE-4F7B-B56D-ED8FB907BEB0Q55088439-D1CC738A-0B1D-4EE7-A669-AE490679F877Q59133918-A2423930-89F7-45F7-B5AE-495B37ADB6C8
P2860
Nanomedicines of Hedgehog inhibitor and PPAR-γ agonist for treating liver fibrosis.
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Nanomedicines of Hedgehog inhibitor and PPAR-γ agonist for treating liver fibrosis.
@ast
Nanomedicines of Hedgehog inhibitor and PPAR-γ agonist for treating liver fibrosis.
@en
type
label
Nanomedicines of Hedgehog inhibitor and PPAR-γ agonist for treating liver fibrosis.
@ast
Nanomedicines of Hedgehog inhibitor and PPAR-γ agonist for treating liver fibrosis.
@en
prefLabel
Nanomedicines of Hedgehog inhibitor and PPAR-γ agonist for treating liver fibrosis.
@ast
Nanomedicines of Hedgehog inhibitor and PPAR-γ agonist for treating liver fibrosis.
@en
P2093
P2860
P1476
Nanomedicines of Hedgehog inhibitor and PPAR-γ agonist for treating liver fibrosis.
@en
P2093
Ram I Mahato
Vaibhav Mundra
Virender Kumar
P2860
P304
P356
10.1007/S11095-013-1239-5
P577
2013-11-19T00:00:00Z